Page 51 - Solid Tumors News Today

/PRNewswire/ -- The "Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.coms...

I-Mab (IMAB) is priced at $46.97 after the most recent trading session. Recently in News on December 15, 2021, I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China. I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmac

– Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months of Follow-Up –BOTHELL, Wash.--(BUSINESS WIRE)--#SABCS2021--Seagen Inc. (Nasdaq:SGEN) today announced the presentation...

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic

/PRNewswire/ -- Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine...

/PRNewswire/ -- Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine...

- Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Cabozantinib showed a favorable safety profile and promising intracranial activity in patients with renal cell carcinoma with brain metastases.